Who we are

InnovaVector is a full-service Contract Development and Manufacturing Organization (CDMO) that offers innovative solutions for the development, production and release of AAV vectors for non-clinical and clinical use.

Our mission

Our mission is to become a leading provider of high quality Adeno-Associated Viral (AAV) vectors for non- clinical and clinical studies.

In vivo gene therapy with adeno-associated viral (AAV) vectors is delivering on its promise as an effective therapeutic strategy given the growing number of clinical trials using this vector platform and the fact that among the first gene therapy products that have recently reached the market in the US and/or the EU three are AAV-based (Glybera, Luxturna and Zolgensma). One major limitation to the clinical development of AAV is the availability of GMP material for clinical trials. InnovaVector has been created to meet the growing demand for GMP AAV batches, accelerating the transfer of existing excellent research on gene therapy from academia to the market and facilitating the development path of new gene therapies.

Our foundations

InnovaVector will be built on the expertise in AAV production, purification and characterisation established at Telethon Institute of Genetics and Medicine, TIGEM, Naples, Italy, in particular within its AAV Vector Core.

TIGEM AAV Vector Core has twenty years experience in the release of research-grade lots of AAV that have been used in dozens of in vitro and in vivo studies in small and large animal models. These studies have shown the ability of these vector preps to transduce rodent tissues including brain, retina, peripheral nerves, skeletal and cardiac muscle and liver as well as the large swine retina and brain. These vector preps have been used to provide pre-clinical evidence of efficacy in models of a rare inborn error of metabolism, mucopolysaccharidosis VI, for which a clinical trial has been initiated. Recently, these preclinical studies have also allowed the development of a gene therapy trial with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB UshTher. Since 2002 TIGEM AAV Vector Core has produced over 3000 preps of AAV and its contribution has been acknowledged in 75 peer-reviewed scientific publications.